Treace Medical Reports Q4 Revenue Decline, Widened Net Loss, and Projects Further Revenue Contraction in 2026
Summary
Treace Medical Concepts reported a 9% revenue decrease for Q4 2025 and a widened net loss for both Q4 and full-year 2025, while also initiating full-year 2026 revenue guidance projecting a further decline of up to 6%.
Key Events
-
Q4 2025 Revenue Decline
Revenue decreased 9% year-over-year to $62.5 million, primarily due to a shift towards lower-priced bunion kits. This confirms the preliminary decline reported on January 13, 2026.
-
Widened Net Loss
The company reported a net loss of $(9.4) million for Q4 2025 and $(59.0) million for full-year 2025, both wider than the prior year periods.
-
Negative 2026 Revenue Guidance
Initiated full-year 2026 revenue guidance of $200 million to $212 million, representing a decline of 0% to 6% compared to 2025. This guidance was previously withheld.
-
Adjusted EBITDA Loss Expected to Widen
Projected full-year 2026 Adjusted EBITDA loss in the range of $4.0 million to $6.0 million, compared to a loss of $(3.9) million in 2025.
Analysis
This filing provides the full Q4 and full-year 2025 financial results, confirming the preliminary Q4 revenue decline previously reported. Crucially, it initiates full-year 2026 guidance, which projects a revenue decline of 0% to 6% and a slightly wider Adjusted EBITDA loss. This indicates continued operational challenges and a negative outlook for top-line growth in the near term, despite efforts to reduce cash usage. Investors should monitor the company's ability to stabilize revenue and improve profitability as guided for the latter half of 2026.
At the time of this filing, TMCI was trading at $2.18 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $133.8M. The 52-week trading range was $1.81 to $10.03. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.